JPRN-UMIN000011798
Recruiting
未知
Pharmacokinetic, pharmacodynamic and pharmacogenetic research on biomarkers in cancer patients with special response to pharmacological therapy - A translational research in cancer patients with special response to pharmacological therapy
Medical Oncology / Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine0 sites600 target enrollmentOctober 1, 2013
ConditionsMalignancy
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malignancy
- Sponsor
- Medical Oncology / Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine
- Enrollment
- 600
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Judged to be inadequate for enrollment by the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Pharmacokinetics, pharmacodynamics and pharmacogenomics of busulphan and other agents used in blood or marrow transplantatioACTRN12612000544875The Children's Hospital at Westmead300
Recruiting
Not Applicable
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancernresectable advanced or recurrent breast cancerJPRN-UMIN000011693ational Cancer Center Hospital50
Completed
Not Applicable
Analysis of pharmacokinetics and pharmacodynamics for capecitabine during new chemotherapy regimen by bevacizumab (Bev) in combination with XELOX in unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000013038Tsukasa Hotta10
Completed
Phase 4
Farmacokinetics and farmacodynamics of drugs used in neonates and children during Extracorporal Membanous Oxygenation (ECMO)patienten aan ECMOheart-lung machineNL-OMON30690Erasmus MC, Universitair Medisch Centrum Rotterdam100
Active, not recruiting
Not Applicable
Clinical trial of galeterone for the treatment of castrate resistant prostate cancerEUCTR2013-003865-32-ESTokai Pharmaceuticals, Inc.24